Atherosclerosis - Pipeline Review, H2 2015 Is Released Atherosclerosis - Pipeline Review, H2 2015 Summary Global Markets Direct s, Atherosclerosis - Pipeline Review, H2 2015, provides an overview of the Atherosclerosiss therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Atherosclerosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Atherosclerosis and special features on late-stage and discontinued projects. Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Atherosclerosis - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Atherosclerosis and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Atherosclerosis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Atherosclerosis pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies Identify emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Atherosclerosis - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Atherosclerosis pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline 1
Browse Complete Report with TOC http://www.idatainsights.com/reports-landingpage.php?id=179104/atherosclerosis-pipeline-review-h2-2015 To Get Sample Copy of Report visit http://www.idatainsights.com/reports-landingpage.php?id=179104/atherosclerosis-pipeline-review-h2-2015 Table of Contents Table of Contents 2 List of Tables 7 List of Figures 8 Introduction 9 Global Markets Direct Report Coverage 9 Atherosclerosis Overview 10 Therapeutics Development 11 Pipeline Products for Atherosclerosis - Overview 11 Pipeline Products for Atherosclerosis - Comparative Analysis 12 Atherosclerosis - Therapeutics under Development by Companies 13 Atherosclerosis - Therapeutics under Investigation by Universities/Institutes 16 Atherosclerosis - Pipeline Products Glance 18 Late Stage Products 18 Clinical Stage Products 19 Early Stage Products 20 Atherosclerosis - Products under Development by Companies 21 Atherosclerosis - Products under Investigation by Universities/Institutes 24 Atherosclerosis - Companies Involved in Therapeutics Development 26 Ache Laboratorios Farmaceuticos S/A 26 advanceCor GmbH 27
2
AFFiRiS AG 28 Arisaph Pharmaceuticals, Inc. 29 Artery Therapeutics, Inc. 30 AstraZeneca Plc 31 Athera Biotechnologies AB 32 AtheroNova Inc. 33 Bayer AG 34 Campus Technologies Freiburg GmbH 35 Cardax Pharmaceuticals, Inc. 36 Cerenis Therapeutics Holding SA 37 ChemoCentryx, Inc. 38 CohBar, Inc. 39 Daiichi Sankyo Company, Limited 40 DoNatur GmbH 41 Dybly AG 42 Exicure, Inc. 43 F. Hoffmann-La Roche Ltd. 44 GenKyoTex S.A. 45 Gilead Sciences, Inc. 46 Jenrin Discovery, Inc. 47 Johnson & Johnson 48 KineMed, Inc. 49 Kowa Company, Ltd. 50 La Jolla Pharmaceutical Company 51 3
Lead Discovery Center GmbH 52 Merck & Co., Inc. 53 MI.TO. Technology S.r.L. 54 Omeros Corporation 55 OPKO Health, Inc. 56 Otsuka Holdings Co., Ltd. 57 Provid Pharmaceuticals, Inc. 58 Resverlogix Corp. 59 The Medicines Company 60 Therapix Biosciences Ltd 61 Tolerys SA 62 Vascular Biogenics Ltd. 63 Vericel Corporation 64 Virocan Therapeutics Private Limited 65 Vitae Pharmaceuticals, Inc. 66 Atherosclerosis - Therapeutics Assessment 67 Assessment by Monotherapy Products 67 Assessment by Combination Products 68 Assessment by Target 69 Assessment by Mechanism of Action 73 Assessment by Route of Administration 76 Assessment by Molecule Type 78 Drug Profiles 80 4
6860766 - Drug Profile 80 AEM-28 - Drug Profile 81 AG-01 - Drug Profile 82 AHRO-001 - Drug Profile 83 AHRO-002 - Drug Profile 85 AHRO-003 - Drug Profile 86 AM-0010 - Drug Profile 87 AmVidcm-009 - Drug Profile 88 anacetrapib - Drug Profile 89 Annexin A-5 - Drug Profile 91 apabetalone - Drug Profile 93 ARI-1778 - Drug Profile 96 Artpep-2 - Drug Profile 97 ATH-03 - Drug Profile 98 ATH-04 - Drug Profile 99 ATH-05 - Drug Profile 100 ATH-06 - Drug Profile 101 AZ-876 - Drug Profile 102 BAY-606583 - Drug Profile 103 BSN-272 - Drug Profile 104 CCX-771 - Drug Profile 105 CDX-085 - Drug Profile 106 Cell Therapy for Atherosclerosis - Drug Profile 108 Cellular Immunotherapy for Atherosclerosis - Drug Profile 109 5
CER-209 - Drug Profile 110 CM-7 - Drug Profile 111 COR-2 - Drug Profile 112 D-4F - Drug Profile 113 DIAS-2 - Drug Profile 114 Drug for Atherosclerosis - Drug Profile 115 Drugs to Activate TLR3 for Atherosclerosis - Drug Profile 116 Drugs to Antagonize NMDA Receptor for Atherosclerosis - Drug Profile 117 DYB-186 - Drug Profile 118 EP-80317 - Drug Profile 119 FX-5A - Drug Profile 120 Gene Therapy for Arteriosclerosis and Endothelial Dysfunction - Drug Profile 121 Gene Therapy to Activate Interleukin 10 for Atherosclerosis - Drug Profile 122 Gene Therapy to Target miR-145 for Atherosclerosis - Drug Profile 123 GKT-831 - Drug Profile 124 GYY-4137 - Drug Profile 125 Humanin - Drug Profile 127 INV-88 - Drug Profile 129 ISIS-APOARx - Drug Profile 130 ITP-01 - Drug Profile 131 ixmyelocel-T - Drug Profile 132 JD-2000 Series - Drug Profile 135 JD-5000 Series - Drug Profile 136 6
JD-6000 Series - Drug Profile 137 K-312 - Drug Profile 138 K-877 - Drug Profile 139 KM-011 - Drug Profile 141 KRP-206 - Drug Profile 142 leucine + niacin - Drug Profile 143 LJPC-6417 - Drug Profile 144 LPC-01 - Drug Profile 145 MCS-18 - Drug Profile 146 MDCO-216 - Drug Profile 148 melittin - Drug Profile 150 Read More http://www.idatainsights.com/reports-landing-page.php?id=179104/atherosclerosispipeline-review-h2-2015 About Us: iData Insights which operates under Precision Research and Consulting Private Limited is a leading market research information aggregator and marketing research consulting firm. We conduct both primary and secondary research. Our work does not end with research it is also involved in distributing reports for different companies . We provide actionable recommendations and provide our expertise for business success today and tomorrow. It is our goal to be a partner to our clients in the exploration and discovery, and then be their guide in the implementation of changes that will make a difference to their bottom line. ContactUs: iData Insights Tel: 1-866-237-2965 Web: http://www.idatainsights.com Email: info@idatainsights.com About iData Insights We work around the clock until our clients are completely satisfied with their promised results. It is our mission to provide timely services coupled with acute client care to create a long-lasting relationship with you. We deliver on our promise to provide results that are essential to the success of your company. We believe that by doing so, we will earn the trust of our clients for future project.
7